Question Bank › Named counterparty roster suddenly upgraded in c

Named counterparty roster suddenly upgraded in caliber

Calls Tested
500
Answered YES
7
Hit Rate
1.4%
rare by design

Amgen Inc. (AMGN) — this company's answers

NO on the Q3 2018 call 2018-10-30 B+
The model's full reasoning — Q3 2018 call → NOWe need answer only YES or NO. Need analyze transcript. Question asks: Does management describe that caliber of counterparties now doing real business with company has recently stepped up — customers/partners/institutions of size/stature/sophistication not previously transacted with are NOW actually buying/deploying/contracting/committing — and management presents upgraded roster as recent change grounded in current transactions, with business still early relative to relationships? Need answer YES only if all three present. We need use only transcript. Let's examine. The transcript is Amgen Q3 2018 earnings call. Management discusses products, launches, biosimilars, etc. Need identify if they describe counterparties of higher caliber recently doing real business. Possibly mention of "Fresenius and DaVita are gradually increasing adoption" for Parsabiv? Those are large dialysis providers. But Amgen has historically served them? EPOGEN, Aranesp, Sensipar to dialysis providers. So not new caliber. Aimovig launch: 12,000 HCPs, 100,000 patients, payers like ESI, Anthem, Kaiser. But Amgen is large pharma, big counterparties unremarkable. Also "we have a great partnership in Japan with our partners Astellas" not new. Biosimilars launched in Europe, tenders in Germany. No explicit "caliber shift" from historical norm. Maybe "newly appointed Head of Global Commercial Operations" etc. Need answer NO. Let's ensure no hidden. The question asks "CALIBER OF COUNTERPARTIES NOW DOING REAL BUSINESS WITH THE COMPANY HAS RECENTLY STEPPED UP" — maybe management mentions "one of the largest PBM" Express Scripts? Murdo says "we've been able to secure coverage at least with one large PBM with ESI" for Aimovig. But Amgen already had relationships with PBMs for other products. Not a caliber shift. Also "Fresenius and DaVita are gradually increasing adoption" for Parsabiv, but these are existing customers for ESAs/calcimimetics. Not new. Thus answer NO.

← Back to the full AMGN analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe that the CALIBER OF COUNTERPARTIES NOW DOING REAL BUSINESS WITH THE COMPANY HAS RECENTLY STEPPED UP — that customers, partners, or institutions of a size, stature, or sophistication the company did not previously transact with are NOW actually buying, deploying, contracting, or committing — and does management present this upgraded roster as a recent change grounded in current transactions, with the associated business still early relative to what those relationships imply? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent development with all three present: (1) A CALIBER SHIFT, RECENTLY OCCURRED: management conveys — by naming counterparties, by describing their category unmistakably ('one of the largest X', 'a national system', 'a top-tier operator'), or by contrasting who buys now versus who used to — that the company has recently begun transacting with a visibly higher class of counterparty than its historical norm; (2) REAL CURRENT BUSINESS, NOT LOGOS: these upgraded counterparties are actually paying, ordering, deploying, or committing now, described with operating substance, not letters of intent, pilots without payment, or pipeline; and (3) EARLY RELATIVE TO THE RELATIONSHIP: management conveys that what these counterparties have taken so far is the beginning — initial orders, first phases, first deployments — with the fuller relationship still ahead of the reported results. Answer NO if the counterparties described are the same kinds the company has always served. NO if the higher-caliber parties are only prospects, in discussions, or unpaid evaluations. NO if the company is itself large so that big counterparties are unremarkable for it. NO if the relationships are mature and fully reflected in results. NO if the upgrade rests on one anecdote management treats as exceptional. NO if the caliber shift appears only in analyst flattery management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
SCPH scPharmaceuticals Inc. Q3 2023 2023-11-08 B
NBTX Nanobiotix S.A. Q2 2023 2023-09-27 D
APPS Digital Turbine, Inc. Q1 2024 2023-08-08 D
EVGO EVgo, Inc. Q2 2022 2022-08-09 C+
VNRX VolitionRx Limited Q1 2022 2022-05-12 F
ASAN Asana, Inc. Q2 2022 2021-09-01 B+
GOGO Gogo Inc. Q1 2016 2016-05-06 C+

How the model reasoned

ASAN · Q2 2022 → YESThe question is about whether management describes that the caliber of counterparties now doing real business with the company has recently stepped up. YES The transcript shows management describing a recent caliber shift to higher-tier enterprise counterparties (Fortune 50 companies with tens of thousands of seats, ViacomCBS, Fujitsu, etc.) that are now conducting real business through larger deals, multiyear agreements, and wall-to-wall deployments.
APPS · Q1 2024 → YESThe question is about whether management describes that the caliber of counterparties now doing real business with the company has recently stepped up. YES Management describes a clear caliber shift with SingleTap: first revenues generated with TikTok (a top-tier social platform), launching with LinkedIn (another major social media company), and expecting a revenue-generating pilot with another large social media company.
EVGO · Q2 2022 → YESThe question is about whether management describes that the caliber of counterparties has recently stepped up, with real current business that's still early.

More from the question bank

The economics improved before the volume arrGeographic or market replication just starteRegular buyers moved from occasional to progConstraint-side candorManagement describes competitors unable to rPhysical throughput records at the operatingAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.